C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
CRON Canadian LP

Cronos Group

NASDAQ · CRON

Canadian LP backed by Altria Group. Focused on disruptive IP and product innovation in cannabis.

Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
60/100 composite
Fundamentals78
Regulatory73
Market40
Editorial30
Composite · trailing 12 months

Cronos Group earns a Neutral rating with a composite score of 60.06, reflecting a company in transition that combines genuine operational momentum with persistent market and visibility headwinds. The fundamentals pillar delivers a robust 78.02, anchored by exceptional 40% year-over-year revenue growth and a gross margin near 40%. Operating margin has reached near-breakeven at negative 1.1%, a marked improvement that positions the company within striking distance of profitability. With a market capitalization exceeding $1 billion and negligible cash burn, Cronos possesses the balance sheet stamina to execute its growth strategy without immediate dilution risk. The regulatory pillar contributes a solid 73.0, underpinned by its Canadian domicile—a jurisdiction scoring 80 on favorable posture—and a clean enforcement record.

The Neutral designation reflects material drag from the market pillar, which registers just 40.0 due to the absence of actionable quote data, and the editorial pillar at 30.0, signaling minimal newsroom or analyst coverage over recent months. This visibility gap constrains investor sentiment despite operational progress. Cronos stands at a crossroads: the revenue trajectory and margin discipline suggest a company finally monetizing its infrastructure, yet the lack of market pricing transparency and media attention limits capital market engagement.

The critical signal to monitor is whether Cronos can restore continuous trading liquidity and attract coverage, transforming operational strength into market recognition that narrows the gap between fundamental performance and investor awareness.

Scored: 2026-07-14Valid through: 2026-08-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
4491 CONCESSION RD 12, STAYNER, A6, L0M 1S0
Phone
(416) 504-0004
SEC CIK
1656472
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$1.03B
Enterprise value
$200.7M
Price to book
0.96
Price to sales
6.44
EV / EBITDA
1.90
Revenue (TTM)
$159.5M
Gross profit (TTM)
$63.2M
EBITDA
$-2K
Operating margin
-1.1%
Profit margin
-1.1%
Rev growth YoY
40.1%
Return on equity
0.4%
Return on assets
-0.8%
EPS est. current year
$0.13
Wall St. target price
$2.51
Shares outstanding
373.7M
Insider ownership
48.5%
Institutional ownership
15.6%
Beta
1.24
Full-time employees
610
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEDAR+
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Cronos Group (CRON)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Cronos Group (CRON), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

Analyst average price target $3.4.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Profitable detected. (3 bullish signals, 1 bearish signal.)

Canadian LP backed by Altria Group. Focused on disruptive IP and product innovation in cannabis.

Latest price: $2.75 (-0.18%) on NASDAQ.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for CRON are maintained by Cannabis Investor News and refreshed throughout the trading day.